News|Videos|February 2, 2024
Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
Author(s)Laura Huppert, MD, Yara Abdou, MD
Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.
Advertisement
Advertisement
Related to this article
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Dr Jabbour on the Significance of the FDA Approval of Orally Disintegrating Nilotinib Tablets for CML
4
Dive Into Key Data and Presentations From EHA 2026
5